** Brokerage H.C. Wainwright starts coverage of drug developer Artiva Biotherapeutics ARTV.O with "buy" rating and PT of $20
** PT represents an ~88% upside to stock's last close
** Co is testing its experimental drug, AlloNK, for an autoimmune disease called systemic lupus erythematosus $(SLE)$ in combination with antibodies Rituxan or Gazyva
** SLE is a condition where the immune system attacks the body's own tissues
** Brokerage notes "current treatment options do not effectively control disease progression"
** Says AlloNK costs less than $6,000 per patient for ARTV to produce, compared to ~$100,000 for auto-CAR T therapies
** Co has capacity to produce enough AlloNK for over 1,000 autoimmune patients annually, H.C. Wainwright says
** Brokerage expects AlloNK to launch by 2029 and forecasts sales to grow to $531 mln by 2031
** As of last close, stock has fallen ~34% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。